COARE is developing therapeutic agents, using strategies that take control and reverse the fundamental mechanisms that cause cancer. Almost all human cancers originate from a cell that has gained properties that resemble epithelial stem cells.
These cells are unique, based on their capacity to renew themselves, give rise to fast-growing cancer cells that make up the tumor, are resistant to radio /chemotherapies, evade the immune system, and change their shape and function in order to spread to different organs (metastasis).

COARE is developing novel platform technologies that include drugs, biologics and cellular-based therapies that simultaneously inactivate and / eliminates these cells while reactivating the immune system to assist in their elimination. COARE has identified a novel master regulatory protein that is responsible for tumor-initiating, progression, and metastases.

COARE has developed first-in-class therapeutic agents that disrupt pro-cancer functions specifically in the critical cells that cause the cancer to grow and spread to distant organs and ultimately cause the death of patients with solid tumor cancers. Indeed, this process called metastasis is responsible for more than 80 percent of the mortality associated with cancer.

COARE’s patented and patent-pending technology has been supported by National Cancer Institute, Department of Veteran Affairs, and philanthropic organizations. The scientific foundation that supports their efforts was developed at the University of Oklahoma Health Sciences Center and has been license to COARE for further development. COARE scientists have collaborated with academic institutions, foundations, and industry towards the development of life-changing anti-cancer medicines that will improve the lives of patients diagnosed with some of the most deadly cancers.

Executive Leadership


Courtney W. Houchen, M.D. is the Regent’s Professor, Eason Chair of Oncology and Chief of the Section of Digestive Diseases & Nutrition in the Department of Medicine at the University of Oklahoma Health Sciences Center. He has over 25 years of experience in the biology of normal and cancer epithelial stem cells. His lab is actively pursuing therapeutic interventions that functionally inactivate or deletes cancer cells that exhibit properties that promote metastasis. He is the founder and currently the Chief Medical Adviser for COARE. He has authored over 100 peer-reviewed manuscripts and abstracts, and book chapters and has active and past funding from the NIH, NCI, VA, DOD and private foundations


Edwin Bannerman-Menson is the CEO of COARE and is a cofounder. He has over 25 years of experience in corporate, business development, and for the last 10 years has been responsible for research and development, fundraising applied research coordination, and commercialization strategy development at COARE. He maintains constant communication with the Federal government, contract research organizations, intellectual property attorneys, and scientific research collaborators in order to fulfill COARE’s business objectives. He is responsible for obtaining millions of dollars in nondilutive NIH funding that has enabled COARE to develop its novel first in class platform technologies